Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 14/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10103385 | 0.98 | HRH3 (0.61) | HRH3MEN1ALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL13849154 | 0.98 | HRH3 (0.61) | HRH3MEN1ALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL10103384 | 0.96 | HRH3 (0.56) | HRH3MEN1ALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL96486 | 0.91 | HRH3 (0.56) | HRH3ALDH1A1CYP2D6KCNH2 | |
| SCHEMBL2331849 | 0.91 | HRH3 (0.56) | HRH3ALDH1A1CYP2D6KCNH2 | |
| SCHEMBL25009132 | 0.90 | HRH3 (0.58) | HRH3MEN1ALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL20325116 | 0.90 | HRH3 (0.52) | HRH3KCNH2 | |
| SCHEMBL11570576 | 0.89 | HRH3 (0.46) | HRH3ALDH1A1 | |
| SCHEMBL1277016 | 0.89 | HRH3 (0.52) | HRH3MEN1ALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL10927336 | 0.89 | HRH3 (0.46) | HRH3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11161841-B2 | Modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-20190315732-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315732-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | MDM2, CRBN, VHL | HRH3 4061/4885MEN1 2058/4885ALDH1A1 2958/4885 |
| US-11161841-B2 | Modulators of proteolysis and associated methods of use | MDM2, CRBN, VHL | HRH3 4061/4885MEN1 2058/4885ALDH1A1 2958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.